Olokizumab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 248 patientsc19early.org

Olokizumab for COVID-19

Serious outcome risk
Olokizumab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−50%
Mortality (1)−50%
RCTs (1)−50%
Late (1)−50%
00.511.5+
← Olokizumab
reduces riskIncreased
risk →
c19early.org
October 2026

Olokizumab COVID-19 studies (1 unreported RCT)

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Samsonov (DB RCT)−50%1.50 · 0.55–4.09death9/1246/124 Samsonov (RCT)n/a< NOT REPORTED >198 (total)RESET>3 years late
Late treatment−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.44
All studies−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+
Rotate screen for more detailsIncrease width for more details
← Olokizumab
reduces riskOlokizumab
increases risk →
c19early.org
October 2026

Olokizumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Samsonov (DB RCT)−50%1.50 · 0.55–4.099/1246/124
Late treatment−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.44
All studies−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+
Rotate screen for more detailsIncrease width for more details
← Olokizumab
reduces riskOlokizumab
increases risk →
c19early.org
October 2026

Olokizumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Samsonov (DB RCT)−50%1.50 · 0.55–4.09death9/1246/124
Late treatment−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.44
All studies−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+
Rotate screen for more detailsIncrease width for more details
← Olokizumab
reduces riskOlokizumab
increases risk →
c19early.org
October 2026

Olokizumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Samsonov (DB RCT)−50%1.50 · 0.55–4.09death9/1246/124 Samsonov (RCT)n/a< NOT REPORTED >198 (total)RESET>3 years late
Late treatment−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.44
All studies−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+
Rotate screen for more detailsIncrease width for more details
← Olokizumab
reduces riskOlokizumab
increases risk →
c19early.org
October 2026

Olokizumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Samsonov (DB RCT)−50%1.50 · 0.55–4.099/1246/124
Late treatment−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.44
All studies−50%1.50 · 0.55–4.099/1246/12450% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+
Rotate screen for more detailsIncrease width for more details
← Olokizumab
reduces riskOlokizumab
increases risk →